Parameter | Mirogabalin add-on group (N = 63) | Conventional treatment group (N = 65) |
---|---|---|
PDAS score | ||
 Baseline, n | 60 | 64 |
  Mean ± SD | 32.3 ± 14.2 | 28.9 ± 14.2 |
   Median (Q1, Q3) | 32.5 (22.0, 44.0) | 27.5 (20.0, 40.0) |
   Min, Max | 0, 57 | 0, 60 |
 Week 8, n | 50 | 53 |
  Mean ± SD | 8.7 ± 9.6 | 11.6 ± 11.1 |
   Median (Q1, Q3) | 4.5 (2.0, 13.0) | 9.0 (2.0, 19.0) |
   Min, Max | 0, 34 | 0, 38 |
  Change from baseline |  − 24.1 ± 14.1 |  − 14.4 ± 14.8 |
   P valuea |  < 0.001 |  < 0.001 |
   P valueb |  < 0.001 | - |
EQ-5D-5L score, index value | ||
 Baseline, n | 60 | 65 |
  Mean ± SD | 0.5179 ± 0.2095 | 0.6153 ± 0.2188 |
   Median (Q1, Q3) | 0.5164 (0.3898, 0.6528) | 0.6392 (0.5187, 0.7791) |
   Min, Max |  − 0.025, 1.000 |  − 0.025, 1.000 |
 Week 8, n | 50 | 53 |
  Mean ± SD | 0.8497 ± 0.1335 | 0.8385 ± 0.1386 |
   Median (Q1, Q3) | 0.8819 (0.7803, 1.0000) | 0.8441 (0.7723, 0.8945) |
   Min, Max | 0.438, 1.000 | 0.455, 1.000 |
  Change from baseline | 0.3363 ± 0.2127 | 0.1798 ± 0.1922 |
   P valuea |  < 0.001 |  < 0.001 |
   P valueb |  < 0.001 | - |